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Percutaneous versus thoracoscopic ablation
of symptomatic paroxysmal atrial
fibrillation: a randomised controlled trial -
the FAST II study
Jesper Eske Sindby1* , Henrik Vadmann2, Søren Lundbye-Christensen3, Sam Riahi2, Søren Hjortshøj2,4,
Lucas V A Boersma5,6 and Jan Jesper Andreasen1,4
Abstract
Background: The most efficient first-time invasive treatment, for achieving sinus rhythm, in symptomatic
paroxysmal atrial fibrillation has not been established. We aimed to compare percutaneous catheter and video-
assisted thoracoscopic pulmonary vein radiofrequency ablation in patients referred for first-time invasive treatment
due to symptomatic paroxysmal atrial fibrillation. The primary outcome of interest was the prevalence of atrial
fibrillation with and without anti-arrhythmic drugs at 12 months.
Methods: Ninety patients were planned to be randomised to either video-assisted thoracoscopic radiofrequency
pulmonary vein ablation with concomitant left atrial appendage excision or percutaneous catheter pulmonary vein
ablation. Episodes of atrial fibrillation were defined as more than 30 s of atrial fibrillation observed on Holter
monitoring/telemetry or clinical episodes documented by ECG.
Results: The study was terminated prematurely due to a lack of eligible patients. Only 21 patients were randomised
and treated according to the study protocol. Thoracoscopic pulmonary vein ablation was performed in 10 patients,
and 11 patients were treated with catheter ablation. The absence of atrial fibrillation without the use of anti-
arrhythmic drugs throughout the follow-up was observed in 70% of patients following thoracoscopic pulmonary
vein ablation and 18% after catheter ablation (p < 0.03).
Conclusion: Thoracoscopic pulmonary vein ablation may be superior to catheter ablation for first-time invasive
treatment of symptomatic paroxysmal atrial fibrillation with regard to obtaining sinus rhythm off anti-arrhythmic
drugs 12 months postoperative.
Trial registration: ClinicalTrials.gov Identifier: NCT01336075. Registered April 15th, 2011.
Keywords: Paroxysmal atrial fibrillation, Catheter ablation, Thoracoscopic, Randomised study
Background
Atrial fibrillation (AF) is characterized by disorganized,
rapid, and irregular contraction of the atria. Its effects
on hemodynamic and thromboembolic events result in
significant morbidity, mortality, impaired quality of life
(QOL), hospitalizations, and health-cost. It is the most
common sustained cardiac arrhythmia. By 2030, it is
estimated that 14–17 millions Europeans will suffer from
this arrhythmia, with 120,000 to 215,000 newly diagnosed
patients per year [1].
Many patients are first diagnosed with AF when they
are admitted to the hospital for AF related event (transient
ischaemic attacks (TIA), stroke etc.). Other patients are
increasingly affected by their symptoms (dyspnoea, palpi-
tations etc.) with episodes increasing in severity and
duration. AF is a progressive disease, where paroxysmal
AF (PAF) can transform into persistent AF, long-standing
persistent and permanent AF.
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The current understanding of the pathophysiology of
AF implies that ‘triggers’ or foci may be located in the
pulmonary veins. Furthermore, electrical and structural
changes of the atrium itself may serve as a ‘substrate’
that can perpetuate AF [1].
AF is treated medically with varying results and there is
no definitive long-term curative treatment. The main goal
aims at reducing symptoms and preventing disabling com-
plications. Treatment normally includes antithrombotic,
rhythm, and/or rate management. The decision regarding
acute or long-term management depends on severity of
the symptoms.
Non-pharmacological interventions have evolved over
the last few decades to prevent and treat atrial fibrillation
and/or to reduce symptoms. These interventions include
catheter ablation (CA), video-assisted thoracoscopic
(VATS) ablation and surgical Maze procedures. Surgical
incisions or lines made by different energy sources, e.g.,
radio frequency or cryo-ablation, inhibit the progression of
electrical impulses from spreading within the atrium [2].
The rationale for eliminating AF with ablation includes
a potential improvement in quality of life [3], a decreased
stroke risk [4] and a decreased heart failure risk and
improved survival.
The long-term results of different treatments modalities
are emerging. However, few randomised trials have been
conducted to compare the surgical and CA modalities.
The Atrial Fibrillation Catheter Ablation Versus Surgical
Ablation Treatment (FAST) study randomized patients
with previously failed CA to thoracoscopic pulmonary
vein ablation (PVI) or repeat CA, which showed signifi-
cantly greater efficacy of VATS PVI, but at the price of a
significantly higher adverse event rate [5]. Other studies
on surgical treatment have shown difference in efficacy
depending on whether patients had paroxysmal, persist-
ent, long-standing persistent or permanent AF and which
lesion-set was made [6].
The most efficient first-time invasive treatment, for
achieving sinus rhythm, in symptomatic paroxysmal
atrial fibrillation has not been established. We aimed to
compare the results of CA versus VATS pulmonary vein
isolation (PVI) as a first invasive treatment in symptom-
atic paroxysmal AF patients. The primary outcome of
interest was the prevalence of AF with and without
anti-arrhythmic drugs (AAD) after 12 months.
Methods
The study was designed as a dual-centre, prospective
randomised study. Two centres were planned to include
and allocate patients 1:1, i.e. the Departments of Cardi-
ology and Cardiothoracic Surgery, Aalborg University
Hospital, Denmark; and the Departments of Cardiology
and Cardiothoracic surgery, St. Antonius Hospital,
Nieuwegein, The Netherlands.
Enrolment began in April 2011 and was planned to
end during the spring of 2013, or when the planned
number of patients was enrolled. Due to administrative
reasons and the relocation of surgical staff, no patients
were included at St. Antonius Hospital.
Eligible patients referred to the Department of
Cardiology, Aalborg University Hospital, Denmark, were
screened, enrolled and randomised through an automatic
digital call centre by cardiologists after oral and written
informed consent from the patient was obtained.
The Danish Ethics Committee approved the study
(VEK project ID: N20110009), and the trial was regis-
tered at ClinicalTrials.gov - Identifier: NCT01336075.
Inclusion criteria
Eligible patients were patients with recurrent symptom-
atic paroxysmal AF. Inclusion criteria were previous fail-
ure with one or more AAD (treatment > 30 days) and/or
cardioversion or any contraindications against treatment
with AADs. ADDs were amiodarone, flecainid, propafe-
none, sotalol, beta-blockers and dronedarone.
Further inclusion criteria were willingness and ability to
attend the scheduled follow-up visits, age between 18 and
75 years, and the provision of signed informed consent.
Exclusion criteria
Exclusion criteria were persistent, long-standing persistent
or permanent AF, a previous AF ablation procedure, AF
secondary to electrolyte imbalance, thyroid disease, a
reversible or non-cardiac cause, severe underlying heart
disease (congenital heart disease, significant valvular
disease, cardiomyopathy with a left ventricular ejection
fraction (LVEF) < 35%, or angina pectoris/ischaemic heart
disease), severe enlargement of the left atrium (> 45 mm),
the presence of a pacemaker, failure to obtain informed
consent, pregnancy or breastfeeding, an inability to
undergo transesophegeal echocardiography (TEE), a docu-
mented left atrial thrombus, the presence of co-morbid
conditions that, in the opinion of the investigator, consti-
tute an increased risk for general anaesthesia or port ac-
cess, e.g., pleural fibrosis, chronic obstructive pulmonary
disease (Forced Expiratory Volume during 1 s. < 1.5 L/s),
known internal carotid artery stenosis (> 80%), current
enrolment in another clinical trial, life expectancy < 1 year,
or previous transient ischaemic attacks (TIA)/stroke.
Procedure
Both CA and VATS PVI are standard treatment options
at Aalborg University Hospital. Approximately 200 CA
procedures are performed annually by three cardiolo-
gists. One surgeon performed all VATS PVI procedures.
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VATS PVI
The procedure was performed under general anaesthesia
with intravenous medication and the placement of a
double-lumen endotracheal tube. TEE was performed in
the operating room (OR) to verify the absence of a left
atrial thrombus before the start of the operation. The
procedure has been described in details by Wolf et al.
[7] and Edgerton et al. [8].
Briefly, three ports were introduced on each side. The
pericardium was incised from the superior vena cava to the
inferior vena cava 2–3 cm anterior and parallel to the
phrenic nerve. Blunt dissection around the pulmonary
veins (PV) was facilitated by an articulated lighted dissector
(Lumitip™ Dissector probe, AtriCure, Inc., Cincinnati,
Ohio). Correct positioning of the ablation clamp (Isolator
Synergy™ Clamp, AtriCure, Inc., Cincinnati, Ohio) on the
atrium and not on the PVs was verified via direct inspection
of the device after closing the jaws of the clamp. Bipolar RF
energy was applied to electrically isolate the PVs; two to five
overlapping lesions were created to ensure isolation. When
the conductance of the tissue decreased to less than 0.0025
Siemens, an audible signal was automatically generated to
indicate that the lesion was transmural. Stimulation with
the Coolrail™ linear pen (AtriCure, Inc., Cincinnati, Ohio)
on the PVs and atria confirmed conductance blockade of
the area.
A chest tube was placed, the right lung was re-inflated,
and the port sites were closed. The technique was
repeated on the left side with the addition of division of
the ligament of Marshall. The left atrial appendage (LAA)
was then excised using a stapling device (EZ 45–60 stap-
ler, Ethicon Endosurgery). LAA exclusion was verified on
TEE. Pacing of the PVs during sinus rhythm was
performed to ensure conductance blockade of the
ablation-lines. No heparin was used during the procedure.
If the patient was not in sinus rhythm by the end of the
procedure, a synchronized direct-current shock was
performed to establish sinus rhythm (SR). Extubation was
performed in the OR.
Percutaneous radiofrequency catheter ablation
Combined with computer tomography scan, a complete
anatomical image of the left atrium was generated with the
CARTO® mapping system (Biosense Webster Inc.,
Diamond Bar, CA, USA), allowing 3-D non-fluoroscopic
navigation in the left atrium. The ablation procedure was
performed as described extensively in the literature by Oral
et al. [9] and Pappone et al. [10]. Briefly, access to the left
atrium was achieved through a standard transseptal punc-
ture using the Brockenbrough technique. Two 8F sheaths
were advanced to the left atrium through two separate
transseptal punctures. During the procedure, unfractio-
nated heparin was administered to maintain an activated
clotting time value > 300 s., measured every 30 min.
Ablation was performed with a 4-mm irrigated tip catheter.
Circumferential ablation lines were performed, encircling
the left and right PVs in the left atrium, with a demonstra-
tion of electrical discontinuity between the PV and the
atrium as an endpoint. Electrical discontinuity was demon-
strated by means of a Lasso catheter placed in the PVs and/
or by the mapping/ablation catheter.
End points
The primary endpoint was freedom from AF/left atrial
tachycardia without antiarrhythmic therapy at 6- and
12-month follow-ups as determined by 7 days of Holter
monitoring, ECG, and patient interviews. AF recurrence
documented by ECG, admission to the hospital due to
AF beyond a blanking period from 3 to 12 months were
also considered treatment failures in addition to
re-intervention.
An episode of AF was defined as more than 30 s of AF
observed on Holter monitoring/telemetry or clinical
symptoms with ECG documentation of AF.
Secondary endpoints were symptom improvement by
the European Heart Rate Association score (EHRA), the
absence of AF/left atrial tachycardia with AADs, proced-
ural complications (local haematomas/ecchymosis,
thromboembolism, vasovagal reaction, haemothorax,
pneumothorax, infection at the entry sites, endocarditis,
pulmonary vein stenosis, cardiac perforation or tampon-
ade, complete heart block, air embolism, arrhythmias,
vascular damage or insufficiency, pericardial effusion,
TIA, pericarditis, phrenic nerve damage, death, sternot-
omy, pain, pneumonia, or chest pain/discomfort), and
reduction of the AF-burden.
Data were collected at follow-up visits at one, three, six
and 12 months and from unplanned admissions to the
hospital and outpatient clinic. Holter monitoring was per-
formed for 7 days shortly before the follow-up visits at six
and 12 months. Information on EHRA-score, medication,
AF recurrence and complications were recorded.
Statistical analysis
A power calculation was performed with a significance
level of 5% and a power of 90% assuming success rates
of 70% and 90% for percutaneous CA and VATS PVI, re-
spectively. Therefore, the study required 79 patients in
each arm. Assuming a dropout rate of 10%, the inclusion
of 90 patients in each arm was planned.
All continuous variables were reported as means and
standard deviations. Comparisons between groups were
conducted using an unpaired t-test with a bootstrap calcu-
lation of standard error to address potential non-normality
and variance inhomogeneity. Categorical variables were re-
ported as numbers and percentages. Comparisons were
conducted using Fisher’s exact test. EHRA scores over time
were analysed using Wald test based on repeated measures
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model. Measures of associations with p-values (two-tailed)
< 0.05 were considered statistically significant. STATA,
version 13.1 (StataCorp, College Station, TX, US) was the
statistical software used.
Results
The study was terminated in January 2014 as only 21 pa-
tients had been enrolled at Aalborg University Hospital.
No patients were included in the Dutch centre due to
administrative reasons and due to relocation of the sur-
gical staff. Termination of the study was due to a lack of
progress in enrolment caused by a lack of patients who
fulfilled the inclusion criteria, as well as administrative
challenges. The first patient was screened in July 2011,
and by November 2013, 209 patients had been screened
for possible enrolment in the study.
Figure 1 shows the patient flow diagram.
Of the screened patients, 165 were excluded accord-
ing to the criteria. Of the remaining 44 patients eligible
for randomization, 22 patients declined participation
after written and oral study information was provided.
A total of 22 patients were randomized. One patient in
the PVI group had a malignant looking nodulus on
chest x-ray and crossed over to CA group after removal
of a pT1aN0M0 adenocarcinoma from the lower right
pulmonary lobe. One patient in CA group was excluded
after the procedure as it turned out the patient had an
underlying atrioventricular nodal re-entrant-tachycardia.
After 6 months of follow-up, one patient in the
VATS PVI group declined further participation in the
study.
Baseline patient characteristics are shown in Table 1.
Efficacy of CA and VATS PVI
Figure 2a and b shows the success-rates with regard to
being in SR at 3-to-6 month, 6-to-12 month and for the
entire 3-to-12 month period after the procedure. Figure
2a shows patients off AAD. Figure 2b shows the
combination of on and off AAD.
Fig. 1 Flow chart of enrolment
Table 1 Patient characteristics
CA VATS PVI
Age at procedure – Years (Mean ± SD) 55.5 (8.1) 53.5 (6.7)
BMI (Mean ± SD) 27.8 (4.4) 28.1 (3.8)
LVEF % (Mean ± SD) 64.5 (4.7) 63.5 (7.1)
LA Diameter – mm (Mean ± SD) 42.2 (3.2) 42.3 (5.1)
DC-conversion pre proc. (Mean ± SD) 2.3 (3.0) 1.5 (3.2)
Sex (Male/Female) 8/3 9/1
Hypertension, n (%) 4 (36.4) 3 (30)
Symptoms - EHRA 2, n (%) 5 (45.5) 5 (50)
Symptoms - EHRA 3, n (%) 6 (54.5) 5 (50)
CHADS2 – score 0, n (%) 4 (36.4) 5 (50)
CHADS2 – score 1, n (%) 4 (36.4) 4 (40)
CHADS2 – score 2, n (%) 3 (27.2) 1 (10)
COPD, n (%) 0 0
Diabetes, n (%) 2 (18.2) 0 (0)
AAD - 0 0 1 (10)
AAD - 1 2 (18.2) 1 (10)
AAD - 2 6 (54.5) 3 (30)
AAD – 3 3 (27.3) 3 (30)
AAD - 4 0 0
AAD - 5 0 2 (20)
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A total of 18% of the patients in the CA group and
70% in VATS PVI group (p < 0.03) achieved SR off AAD
for the entire postoperative blanking period. For patients
both on and off AAD the results were 27% versus 100%,
respectively (p < 0.001).
The results from Holter monitoring after CA at six
and 12 months showed 80% and 70% in SR +/− AADs,
respectively. For VATS PVI, the results showed 100% in
SR +/− AADs at 6 and 12 months.
At the 6-month follow-up, two patients lacked 7-day
Holter monitoring data and two patients lacked Holter
monitoring data at the 12-month follow-up. The Holter
monitoring data at six and 12 months showed that two
and three different patients respectively, all in the CA
group, had documented AF.
No patients suffered a stroke, TIA or bleeding compli-
cations during the follow-up.
Figure 3 depicts development of symptoms, classified in
EHRA-score, from before the procedure to 12 month after.
Safety of CA and VATS PVI (Tables 2 and 3)
Discussion
In this randomised clinical trial, VATS PVI was compared
with CA as a first-time invasive treatment for patients
with paroxysmal AF. The results from this limited number
of patients indicated that VATS PVI might be superior to
CA for the first-time invasive treatment of paroxysmal AF
relative to the primary endpoint of freedom from AF with-
out AADs at 12 months. However, the VATS PVI proced-
ure resulted in a higher rate of complications and an
increased length of hospital stay. Due to the premature ter-
mination of the study, no solid conclusions can be drawn.
A
B
Fig. 2 a Patients achieving SR off anti arrhythmic drugs. b Patients achieving SR on and off anti arrhythmic drugs
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For the entire follow-up period, VATS PVI was signifi-
cantly better at achieving SR without AADs.
The optimal follow-up would have been continuous
monitoring of the heart rhythm for the entire period as
suggested by The Society of Thoracic Surgeons [11]. We
present the results from the different time periods along
with the scheduled Holter monitoring at 6 and 12 month
including the success-rate for the entire follow-up (3 to
12 month) as it somewhat resembles a continuous
monitoring.
Our dataset is too small to assess reliable differences
in success rates between the different time periods
within the CA and VATS PVI groups. Most AF relapses
occurred outside the scheduled Holter monitoring
period. A 7-day Holter monitoring covers only a small
portion of the follow-up period. Similar monitoring
issues could be suspected when comparing results from
the present study with other studies.
No pre-operative Holter monitoring was performed, so
a comparison with 7-day Holter monitoring at six and
12 months could not be done. According to the Holter
monitoring data, five patients showed various degrees of
AF-burden (from 0.1 to 99.9%) in the CA group.
The Atrial Fibrillation Catheter Ablation Versus Surgical
Ablation Treatment (FAST) study [5] randomized patients
with previously failed CA to VATS pulmonary vein isola-
tion (PVI) or repeat CA and showed significantly greater
efficacy with VATS PVI, but at the cost of a higher adverse
event rate. Their results showed absence of AF without
AADs at 12 months at 36,5% for CA and 65,6% for VATS
PVI. However, the patients in the FAST-study differed
from the patients in the present study in that some had
paroxysmal AF, persistent AF and/or an enlarged left
atrium and previously failed CA. Patients with an enlarged
atria and persistent AF especially, have lower success rates
with PVI as the only treatment and could account for the
failures in the FAST-study.
A recent review article on VATS PVI by Laar et al.
[12] showed an efficacy rate of VATS PVI of 81% at 1
year (SR off AAD), which is similar to our results.
Different strategies for post-procedure monitoring have
been applied in many studies and all have their strengths
and weaknesses. Mostly, 1- to 7-day Holter monitoring has
been used because it is relatively easy to apply and is
patient-friendly. Unfortunately, it only covers a small
Fig. 3 EHRA-score over time
Table 2 Procedure characteristics
CA VATS PVI
Procedure time 174 min 168.5 min
Grey/Radiation 28 Gy (Range 12–61) 0
Admitted – Days 1 (SD 0) 7.6 (Range 3–21)
Removal of LAA 0% 100%
Procedural endpoint achieved 100% 100%
CA Catheter Ablation, VATS PVI Video Assisted Thoracoscopic Pulmonary Vein
Isolation, Gy Grey, SD Standard Deviation, LAA Left Atrial Appendage
Table 3 Complications
CA VATS PVI
Procedure complications 0 1a
Complications during hospitalization 0 2b
Complications 1 month 1c 0
Complications 3 month 0 0
Complications 6 month 1d 0
Complications 12 month 0 0
CA Catheter Ablation, VATS PVI Video Assisted Thoracoscopic Pulmonary
Vein Isolation
a The patient was converted to sternotomy due to bleeding. A full Maze IV
was performed and the patient was discharged on post-operative day five
without any further events; b One patient with heart block which resolved
spontaneously and one patient with tamponade (relived with percutaneous
drainage) and pneumonia; c Patient had discomfort in the chest and resolved
within a few days without treatment; d Re-ablated and pacemaker insertion
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fraction of the entire follow-up period. Pappone et al. [10]
reported an average of 6 ± 4 AF episodes per month prior
to treatment. A 24-h Holter monitoring would have an
approximate 20% chance of detecting AF based on those
numbers. Jaïs et al. [13] showed 4–30 episodes per month
in which the average episode lasted 5.5 h (range 1–12 h).
Therefore, Holter monitoring may have a very good
positive predictive value but a low negative predictive value
in this setting.
In a review article by Kis et al. on CA PVI treatment
[14] showed a success rate of 78% (freedom from AF both
on and off AADs) based on the majority of the included
studies having 24-h Holter monitoring at different time
intervals as a reflection of success. In our opinion, this
would generally be insufficient to detect asymptomatic
episodes of AF.
Because of different follow-up strategies, it is difficult
to compare our CA results with others.
We suggest reporting data for the entire follow-up
period and following patients for at least 1 year, preferably
longer. Insertable Cardiac Monitor devices may be pre-
ferred in the future as they are becoming smaller and less
expensive, and these devices can detect AF/Arrhythmia
on a continuous basis for a longer period depending on
the battery capacity [15]. However, there is risk of ‘noise’
and hence over-estimation of AF/arrhythmia.
Three out of five patients were reluctant to participate
in the study, although the reason remained unspecified
for the majority. Patients have different preferences and
intentions when they come to the specialists; some
choose for 100% efficacy, others choose for minimal im-
pact and therefore they do not want to be randomized
in a scientific study.
EHRA scores decreased over time in both groups, but
improved more in the VATS PVI group than in the CA
group, possibly due to the higher success rate of VATS
PVI, even though CA has been shown to decrease the
frequency and severity of symptoms [13].
The LARIAT-study showed a decrease in AF-burden
after ligation of the LAA without any ablation [16]. This
finding is of interest in relation to the present study as a
major procedural difference between VATS PVI and CA
was exclusion of the LAA. In a study by Di Biase et al.
[17], it was shown that 27% of failed CA procedures
occurred in patients with initiation/trigger points for AF
in or around the LAA, which could partly explain the
higher success rate with VATS PVI as the LAA is
excluded. Romanov et al. [18] have found no difference
in success rates when removing the LAA in patients
with non-paroxysmal AF.
Ligation of the LAA as the only treatment [19] has
shown a persistent decrease in blood pressure (BP) and a
short-term reduction in sodium levels. Neuro-hormonal
changes are still unclear, but indicate that AF could be
much more than just a ‘mechanical’ problem of irregular
heartbeats.
Concerning matters of LAA, one should notice that
this study was not designed nor powered for a compari-
son of ablation lines but in order to compare two inva-
sive treatment procedures.
Complications occurred more often in the surgical
group as also shown by others authors [1, 5, 12]. The
main reasons for prolonged hospital stays in the present
study were pneumonia, temporary heart block and pain
management. Complications in the VATS PVI group
were dealt with during the hospital stay and none of the
patients had problems after discharge. Laar et al. [12]
showed a complication rate similar to CA after minor
complications e.g. pneumothorax and pleural effusions
were excluded from analysis.
Even though the objectives of the procedures are similar,
the risk-profiles of CA and VATS PVI are different [1]. To
optimize communication with patients, complications
may be classified as life-threatening, severe, moderate,
minor and unknown as outlined in published guidelines
[1]. The risk-profile and long-term benefits of a procedure
should be taken into consideration and conveyed to the
patient when choosing a treatment strategy.
A major limitation of this study is the low number of
patients included, and therefore the study was not
powered for firm conclusions.
Conclusion
VATS PVI may be superior to CA for the first-time inva-
sive treatment of symptomatic paroxysmal AF in obtain-
ing freedom from AF without AADs 12 months
postoperative. However, a higher rate of complications
and longer hospitalization is associated with VATS PVI.
Although this was a randomised study, no solid conclu-
sions can be drawn based on the results from this study
due to the low number of patients included. A similar
study should be carried out in centres with more patients.
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